2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases
By V. Furer, C. Rondaan, M. Heijstek, N. Agmon-Levin, S. van Assen, M. Bijl, F. Breedveld, R. D'Amelio, M. Dougados, M. Kapetanovic and 11 more. Annals of the Rheumatic Diseases, 2019
682 citations recorded by the source corpus.
To update the European League Against Rheumatism (EULAR) recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD) published in 2011. Four systematic literature reviews were performed regarding the incidence/prevalence of vaccine-preventable infections among patients with AIIRD; efficacy, immunogenicity and safety of vaccines; effect of anti-rheumatic drugs on the response to vaccines; effect of vaccination of household of AIIRDs patients. Subsequently, recommendations were formulated based on the evidence and expert opinion. The updated recommendations comprise six overarching principles and nine recommendations. The former address the need for an annual vaccination status assessment, shared decision-making and timing of vaccination, favouring vaccination during quiescent disease, preferably prior to the initiation of immunosuppression. Non-live vaccines can be safely provided to AIIRD patients regardless of underlying therapy, whereas live-attenuated vaccines may be considered with caution. Influenza and pneumococcal vaccination should be strongly considered for the majority of patients with AIIRD. Tetanus toxoid and human papilloma virus vaccination should be provided to AIIRD patients as recommended for the general population. Hepatitis A, hepatitis B and herpes zoster vaccination should be administered to AIIRD patients at risk. Immunocompetent household members of patients with AIIRD should receive vaccines according to national guidelines, except for the oral poliomyelitis vaccine. Live-attenuated vaccines should be avoided during the first 6 months of life in newborns of mothers treated with biologics during the second half of pregnancy. These 2019 EULAR recommendations provide an up-to-date guidance on the management of vaccinations in patients with AIIRD.
Subfields: Hematology, Immunology, Rheumatology
View Paper: https://www.semanticscholar.org/paper/8305c8532e5a285b748192672ad88b6a08926bea
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- E. Morand
- R. Furie
- M. Kostopoulou
- Jeanette Andersen
- S. Navarra
- M. Aringer
- F. Houssiau
- I. Bruce
Citations in the corpus
- EULAR recommendations for the management of systemic lupus erythematosus: 2023 update (2023, background): “104 105 Similarly, several observational studies have proven the immunogenicity and safety of SARS- CoV-2 vaccines, which are recommended for patients with SLE.”